356 related articles for article (PubMed ID: 29653567)
1. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
2. A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.
Toor JS; Rao AA; McShan AC; Yarmarkovich M; Nerli S; Yamaguchi K; Madejska AA; Nguyen S; Tripathi S; Maris JM; Salama SR; Haussler D; Sgourakis NG
Front Immunol; 2018; 9():99. PubMed ID: 29441070
[TBL] [Abstract][Full Text] [Related]
3. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity.
Duan F; Duitama J; Al Seesi S; Ayres CM; Corcelli SA; Pawashe AP; Blanchard T; McMahon D; Sidney J; Sette A; Baker BM; Mandoiu II; Srivastava PK
J Exp Med; 2014 Oct; 211(11):2231-48. PubMed ID: 25245761
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.
Türeci Ö; Vormehr M; Diken M; Kreiter S; Huber C; Sahin U
Clin Cancer Res; 2016 Apr; 22(8):1885-96. PubMed ID: 27084742
[TBL] [Abstract][Full Text] [Related]
5. Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival.
Wood MA; Weeder BR; David JK; Nellore A; Thompson RF
Genome Med; 2020 Mar; 12(1):33. PubMed ID: 32228719
[TBL] [Abstract][Full Text] [Related]
6. An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes.
Bjerregaard AM; Nielsen M; Jurtz V; Barra CM; Hadrup SR; Szallasi Z; Eklund AC
Front Immunol; 2017; 8():1566. PubMed ID: 29187854
[TBL] [Abstract][Full Text] [Related]
7. Characterizing neoantigens for personalized cancer immunotherapy.
Capietto AH; Jhunjhunwala S; Delamarre L
Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
[TBL] [Abstract][Full Text] [Related]
8. The neoepitope landscape in pediatric cancers.
Chang TC; Carter RA; Li Y; Li Y; Wang H; Edmonson MN; Chen X; Arnold P; Geiger TL; Wu G; Peng J; Dyer M; Downing JR; Green DR; Thomas PG; Zhang J
Genome Med; 2017 Aug; 9(1):78. PubMed ID: 28854978
[TBL] [Abstract][Full Text] [Related]
9. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
10. Novel tools to assist neoepitope targeting in personalized cancer immunotherapy.
Saini SK; Rekers N; Hadrup SR
Ann Oncol; 2017 Dec; 28(suppl_12):xii3-xii10. PubMed ID: 29092006
[TBL] [Abstract][Full Text] [Related]
11. Circular RNA as a source of neoantigens for cancer vaccines.
Ren Y; Manoharan T; Liu B; Cheng CZM; En Siew B; Cheong WK; Lee KY; Tan IJ; Lieske B; Tan KK; Chia G
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38508656
[TBL] [Abstract][Full Text] [Related]
12. IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition.
Borch A; Carri I; Reynisson B; Alvarez HMG; Munk KK; Montemurro A; Kristensen NP; Tvingsholm SA; Holm JS; Heeke C; Moss KH; Hansen UK; Schaap-Johansen AL; Bagger FO; de Lima VAB; Rohrberg KS; Funt SA; Donia M; Svane IM; Lassen U; Barra C; Nielsen M; Hadrup SR
Front Immunol; 2024; 15():1360281. PubMed ID: 38633261
[TBL] [Abstract][Full Text] [Related]
13. Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information.
Kim S; Kim HS; Kim E; Lee MG; Shin EC; Paik S; Kim S
Ann Oncol; 2018 Apr; 29(4):1030-1036. PubMed ID: 29360924
[TBL] [Abstract][Full Text] [Related]
14. Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors.
Roudko V; Bozkus CC; Orfanelli T; McClain CB; Carr C; O'Donnell T; Chakraborty L; Samstein R; Huang KL; Blank SV; Greenbaum B; Bhardwaj N
Cell; 2020 Dec; 183(6):1634-1649.e17. PubMed ID: 33259803
[TBL] [Abstract][Full Text] [Related]
15. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
16. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data.
Zhou C; Wei Z; Zhang Z; Zhang B; Zhu C; Chen K; Chuai G; Qu S; Xie L; Gao Y; Liu Q
Genome Med; 2019 Oct; 11(1):67. PubMed ID: 31666118
[TBL] [Abstract][Full Text] [Related]
17. HLA-binding properties of tumor neoepitopes in humans.
Fritsch EF; Rajasagi M; Ott PA; Brusic V; Hacohen N; Wu CJ
Cancer Immunol Res; 2014 Jun; 2(6):522-9. PubMed ID: 24894089
[TBL] [Abstract][Full Text] [Related]
18. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens.
Mortier MC; Jongert E; Mettens P; Ruelle JL
BMC Immunol; 2015 Oct; 16():63. PubMed ID: 26493839
[TBL] [Abstract][Full Text] [Related]
19. Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy.
Shah RK; Cygan E; Kozlik T; Colina A; Zamora AE
Front Immunol; 2023; 14():1301100. PubMed ID: 38149253
[TBL] [Abstract][Full Text] [Related]
20. Cancer Neoantigens and Applications for Immunotherapy.
Desrichard A; Snyder A; Chan TA
Clin Cancer Res; 2016 Feb; 22(4):807-12. PubMed ID: 26515495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
